Healthcare sustainability hinges on investing in healthcare companies that save costs as well as lives

Investors stand to play a crucial role in driving healthcare sustainability as well as supporting scientific innovation, write Nathalie Flury (above, left) and Michael Schröter, founding partners at Swiss asset manager Viopas Partners, and Kate Dion, healthcare value communications consultant at 3D Communications, in an Expert View piece.

Strategic investments in pharmaceutical and biotech companies that focus on cost-saving breakthrough therapies may also deliver stronger returns.

It’s no secret that payers are struggling to balance ever-tighter drug budgets with an explosion in the number of high-cost medicines coming onto the market. Understandably, budget holders are applying increasingly stringent decision-making criteria as they seek to keep control of their purse strings. This is impacting the bottom lines and reputations of companies as well as patients’ ability to access and benefit from important scientific advances.